

BEXIMCO PHARMACEUTICALS LIMITED

17, DHANMONDI, ROAD NO. 2,
DHAKA-1205

PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of the Company in their meeting held on 25 October, 2017 at 3.30 p.m. has approved the audited Financial Statements for the year ended 30 June, 2017 and took the following decisions:

1. Recommended Dividend : 12.5% Cash Dividend.
2. Record date : 15 November, 2017.
3. Date & Time of 41st AGM : 23 December, 2017 at 10.00 A.M.
4. Venue of 41st AGM : Beximco Industrial Park, Sarabo,
Kashimpur, Gazipur.

5. Comparative Financial Disclosure:

Amount in Taka

Particulars	July 2016 - June 2017 (12 Months)	January 2015 - June 2016 (18 Months)	January - June 2016 (6 Months)	January - December 2015 (12 Months)
Profit after Tax	2,226,695,124	2,948,053,854	993,769,338	1,954,284,516
Earnings Per Share (EPS)/ Adjusted EPS	5.49	7.27	2.45	4.82

	June 30, 2017	June 30, 2016
Net Asset Value (NAV)	25,072,425,900	23,059,412,409
Net Asset Value Per Share (NAVPS)	61.82	59.70

	July 2016 - June 2017 (12 Months)	January 2015 - June 2016 (18 Months)
Net Operating Cash Flow Per Share (NOCFPS)	6.49	8.21

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

Dated: 25 October, 2017

